Difference between revisions of "Strategic Tissue Repository Alliance through Unified Methods"
| Line 3: | Line 3: | ||
"Public engagement" for the project is managed by [[Genetic Alliance UK]].<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref> | "Public engagement" for the project is managed by [[Genetic Alliance UK]].<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref> | ||
| − | STRATUM is one of seven projects under the umbrella of the [[Stratified Medicine Innovation Platform]] (SMIP), a "personalised medicine" initiative led by the [[Technology Strategy Board]], which in turn is an executive non-departmental public body established by the UK Government in 2007 and sponsored by the [[Department for Business, Innovation and Skills]] (BIS). The seven projects are led by [[AstraZeneca]] UK Ltd, [[GlaxoSmithKline]], [[Ig Innovations]] Ltd, [[Janssen]] UK and [[Randox Laboratories]] Ltd. The Technology Strategy Board and the [[Medical Research Council]] invested over GBP 3.7 million of public money in the seven projects.<ref>Technology Strategy Board (2011) [http://bit.ly/VaygFa Research and development into personalised medicine to receive new government investment], press release, 19 May, acc 30 Nov 2012</ref> | + | STRATUM is one of seven projects under the umbrella of the [[Stratified Medicine Innovation Platform]] (SMIP), a "personalised medicine" initiative led by the [[Technology Strategy Board]], which in turn is an executive non-departmental public body established by the UK Government in 2007 and sponsored by the [[Department for Business, Innovation and Skills]] (BIS). The seven projects are led by [[AstraZeneca]] UK Ltd, [[GlaxoSmithKline]], [[Ig Innovations]] Ltd, [[Janssen|Janssen Pharmaceutica]] UK and [[Randox Laboratories]] Ltd. The Technology Strategy Board and the [[Medical Research Council]] invested over GBP 3.7 million of public money in the seven projects.<ref>Technology Strategy Board (2011) [http://bit.ly/VaygFa Research and development into personalised medicine to receive new government investment], press release, 19 May, acc 30 Nov 2012</ref> |
==Notes== | ==Notes== | ||
<references/> | <references/> | ||
[[Category:GM]][[Category:Human Genetics]] | [[Category:GM]][[Category:Human Genetics]] | ||
Revision as of 14:50, 30 November 2012
STRATUM (Strategic Tissue Repositaory Alliance through Unified Methods) is a biobanking (storage of human tissue samples for research) project, described as "a collaboration between the pharmaceutical industry and academia, led by AstraZeneca". Other partners of the consortium include GlaxoSmithKline, Lab21 and the universities of Manchester, Nottingham and Leicester.[1]
"Public engagement" for the project is managed by Genetic Alliance UK.[2]
STRATUM is one of seven projects under the umbrella of the Stratified Medicine Innovation Platform (SMIP), a "personalised medicine" initiative led by the Technology Strategy Board, which in turn is an executive non-departmental public body established by the UK Government in 2007 and sponsored by the Department for Business, Innovation and Skills (BIS). The seven projects are led by AstraZeneca UK Ltd, GlaxoSmithKline, Ig Innovations Ltd, Janssen Pharmaceutica UK and Randox Laboratories Ltd. The Technology Strategy Board and the Medical Research Council invested over GBP 3.7 million of public money in the seven projects.[3]
Notes
- ↑ Genetic Alliance UK (2012) Project: Understanding public engagement with biobanking, acc 30 Nov 2012
- ↑ Genetic Alliance UK (2012) Project: Understanding public engagement with biobanking, acc 30 Nov 2012
- ↑ Technology Strategy Board (2011) Research and development into personalised medicine to receive new government investment, press release, 19 May, acc 30 Nov 2012
